Literature DB >> 2571423

Bolus administration of esmolol for the treatment of intraoperative myocardial ischaemia.

D R Miller1, R J Martineau.   

Abstract

We report the successful treatment with esmolol of intraoperative myocardial ischaemia associated with concurrent hypertension and tachycardia, in a patient with risk factors for coronary artery disease undergoing peripheral vascular surgery. The pathophysiology of myocardial ischaemia, and the therapeutic role of beta blocking drugs are briefly reviewed. Esmolol, a short-acting cardioselective beta blocking drug, was administered in a bolus of 1.5 mg.kg-1, and resulted in prompt resolution of the haemodynamic abnormalities, with concomitant restitution of the ST segments to isoelectric baseline. We conclude that bolus administration of esmolol is practical and can be effective for the treatment of intraoperative myocardial ischaemia.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2571423     DOI: 10.1007/BF03005392

Source DB:  PubMed          Journal:  Can J Anaesth        ISSN: 0832-610X            Impact factor:   5.063


  20 in total

1.  First ultra-short-acting beta-adrenergic blocking agent: its effect on size and segmental wall dynamics of reperfused myocardial infarcts in dogs.

Authors:  R Lange; R A Kloner; E Braunwald
Journal:  Am J Cardiol       Date:  1983-06       Impact factor: 2.778

2.  Isoflurane--a powerful coronary vasodilator in patients with coronary artery disease.

Authors:  S Reiz; E Bålfors; M B Sørensen; S Ariola; A Friedman; H Truedsson
Journal:  Anesthesiology       Date:  1983-08       Impact factor: 7.892

Review 3.  Experimental and clinical observations on the efficacy of esmolol in myocardial ischemia.

Authors:  R A Kloner; J Kirshenbaum; R Lange; E M Antman; E Braunwald
Journal:  Am J Cardiol       Date:  1985-10-23       Impact factor: 2.778

4.  Does perioperative myocardial ischemia lead to postoperative myocardial infarction?

Authors:  S Slogoff; A S Keats
Journal:  Anesthesiology       Date:  1985-02       Impact factor: 7.892

Review 5.  Propranolol and experimental myocardial infarction: substrate effects.

Authors:  L H Opie; M Thomas
Journal:  Postgrad Med J       Date:  1976       Impact factor: 2.401

6.  Myocardial metabolism and hemodynamic responses with isoflurane anesthesia for coronary arterial surgery.

Authors:  E A Moffitt; R A Barker; J J Glenn; D D Imrie; C DelCampo; R W Landymore; C E Kinley; D A Murphy
Journal:  Anesth Analg       Date:  1986-01       Impact factor: 5.108

7.  Esmolol attenuates hemodynamic responses during fentanyl-pancuronium anesthesia for aortocoronary bypass surgery.

Authors:  L R Newsome; J V Roth; C C Hug; D Nagle
Journal:  Anesth Analg       Date:  1986-05       Impact factor: 5.108

8.  Cardiovascular effects of esmolol in anesthetized humans.

Authors:  P G Menkhaus; J G Reves; I Kissin; J M Alvis; A V Govier; P N Samuelson; W A Lell; C E Henling; E Bradley
Journal:  Anesth Analg       Date:  1985-03       Impact factor: 5.108

9.  Effects of bolus injection of esmolol in healthy, exercising subjects.

Authors:  K A Ellenbogen; E A McCarthy; E L Pritchett
Journal:  Clin Pharmacol Ther       Date:  1987-04       Impact factor: 6.875

10.  Perioperative myocardial ischemia: importance of the preoperative ischemic pattern.

Authors:  A A Knight; M Hollenberg; M J London; J Tubau; E Verrier; W Browner; D T Mangano
Journal:  Anesthesiology       Date:  1988-05       Impact factor: 7.892

View more
  4 in total

1.  Esmolol--just another beta blocker?

Authors:  R I Hall
Journal:  Can J Anaesth       Date:  1992-10       Impact factor: 5.063

2.  Esmolol.

Authors:  J G Ramsay
Journal:  Can J Anaesth       Date:  1991-03       Impact factor: 5.063

3.  Rate-pressure product.

Authors:  B O'Sullivan
Journal:  Can J Anaesth       Date:  1990-04       Impact factor: 5.063

4.  Bolus application of landiolol and esmolol: comparison of the pharmacokinetic and pharmacodynamic profiles in a healthy Caucasian group.

Authors:  Günther Krumpl; Ivan Ulc; Michaela Trebs; Pavla Kadlecová; Juri Hodisch
Journal:  Eur J Clin Pharmacol       Date:  2017-01-13       Impact factor: 2.953

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.